Principal Investigator
Robert Kirsner
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20230072
Clinical Trial Summary
A Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors
Phase
Phase II
Funding Agency/Sponsor
Industrial
Disease
Cutaneous Malignancies
Contact Information
Phone Number
305-243-2647